We are delighted to announce we have initiated a strategic collaboration with WuXi Biologics to develop and manufacture xB3-001, our lead investigational candidate to treat HER2+ breast cancer brain metastases. To learn more, please visit:

https://www.bioasis.us/bioasis-and-wuxi-biologics-announce-initial-strategic-collaboration-for-the-development-and-manufacturing-of-xb3-001-the-companys-lead-investigational-candidate-to-treat-brain-cancer/